COVID-19’s adverse impact on the cardiovascular system

COVID-19 can cause serious cardiovascular complications including heart failure, heart attacks and blood clots that can lead to strokes, emergency medicine doctors report in a new scientific paper. They also caution that COVID-19 treatments can interact with medicines used to manage patients' existing cardiovascular conditions.

The new paper from UVA Health's William Brady, MD, and colleagues aims to serve as a guide for emergency-medicine doctors treating patients who may have or are known to have COVID-19. The authors note that much attention has been paid to the pulmonary (breathing) complications of COVID-19, but less has been said about the cardiovascular complications that can lead to death or lasting impairment.

In writing this article, we hope to increase emergency physicians' knowledge and awareness of this new pathogen and its impact on the cardiovascular system. As we encounter more and more patients with COVID-19-related illness, we are increasing our understanding of its impact on the body in general and the cardiovascular system in particular. The rate of learning on this area is amazingly rapid. Information continues to change weekly, if not daily."

William Brady, MD, UVA's Department of Emergency Medicine

COVID-19 and heart failure

Heart failure is a particular concern in patients with COVID-19. One study, the article authors note, found that almost a quarter of COVID-19 patients – 24% – were suffering acute heart failure when they were first diagnosed with the coronavirus. (This doesn't mean that 24% of all COVID-19 patients will suffer heart failure. The authors state that it remains unclear if the heart failure was the result of COVID-19 specifically or if the virus was worsening undiagnosed heart failure.)

Of the patients with heart failure, nearly half were not known to have high blood pressure or cardiovascular disease.

Strokes and other concerns

The paper also notes that COVID-19, and other diseases that cause severe inflammation throughout the body, increase the risk that fatty plaque built up in the blood vessels will rupture, leading to heart attacks and stroke. Influenza and certain other viruses have been associated with increased risk of plaque ruptures within the first week after the disease was diagnosed, the authors state in their review of the available COVID-19 medical literature.

Finally, the authors describe potential drug interactions in COVID-19 patients. For example, the highly publicized malaria drug hydroxychloroquine can interact with medications designed to regulate heart rhythm, in addition to causing heart damage and worsening cardiomyopathy. Remdesivir, an antiviral that is the only COVID-19 treatment authorized by the FDA, can cause low blood pressure and abnormal heart rhythm. It's important for doctors to bear these interactions in mind when treating patients with COVID-19, the authors note.

"As we gain more experience with this new pathogen, we realize that its adverse impact extends beyond the respiratory system," Brady said. "We will continue to learn more about COVID-19 and the most optimal means of managing its many presentations."

Findings published

The article has been published online by the American Journal of Emergency Medicine. In addition to Brady, it was written by Brit Long, MD, of Brooke Army Medical Center; Alex Koyfman, MD, of the University of Texas Southwestern Medical Center; and Michael Gottlieb, MD, of Rush University Medical Center.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients